Novo Nordisk
NVO
$125.26
Share price
2.08%
Change (1 day)
46.95%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Cash on Hand
Cash on Hand as of December 2023 : $4.47 B
According to Novo Nordisk's latest financial reports the company has $4.47 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Novo Nordisk - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $4.47 B | 31.88% |
| 2022-12-31 | $3.39 B | 27.53% |
| 2021-12-31 | $2.66 B | 26.24% |
| 2020-12-31 | $2.10 B | -9.12% |
| 2019-12-31 | $2.32 B | -3.16% |
| 2018-12-31 | $2.39 B | -21.17% |
| 2017-12-31 | $3.03 B | 3.7% |
| 2016-12-31 | $2.93 B | -2.28% |
| 2015-12-31 | $2.99 B | 15.45% |
| 2014-12-31 | $2.59 B | -3.03% |
| 2013-12-31 | $2.67 B | -6.19% |
| 2012-12-31 | $2.85 B | -6.34% |
| 2011-12-31 | $3.04 B | 6.44% |
| 2010-12-31 | $2.86 B | 15.94% |
| 2009-12-31 | $2.47 B | 29.19% |
| 2008-12-31 | $1.91 B | 32.34% |
| 2007-12-31 | $1.44 B | 59.73% |
| 2006-12-31 | $0.90 B | 13.87% |
| 2005-12-31 | $0.79 B | 9.4% |
| 2004-12-31 | $0.72 B | 38.6% |
| 2003-12-31 | $0.52 B | 110.69% |
| 2002-12-31 | $0.24 B | -42.9% |
| 2001-12-31 | $0.43 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $12.69 B | 183.44% | 🇺🇸 USA |
 Eli Lilly LLY | $2.92 B | -34.61% | 🇺🇸 USA |
 Sanofi SNY | $9.92 B | 121.75% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | $12.28 B | 174.28% | 🇺🇸 USA |